ライフサイエンスコーパス: matching placebo

1 istered as one 250-mg gefitinib tablet and 1 matching placebo).

2 re treated either with lamivudine (n = 406), matching placebo (n = 196), interferon (n = 68), or the

3 medroxyprogesterone acetate (n = 2229), or a matching placebo (n = 2303).

4 ed to receive either 300 mg clopidogrel or a matching placebo administered a minimum of 3 h and a max

5 received 1 mg crystalline vitamin B-12 or a matching placebo as a daily oral tablet for 12 mo.

6 parib (as capsules; 400 mg twice a day) or a matching placebo by an interactive voice response system

7 release niacin and 40 mg of laropiprant or a matching placebo daily.

8 y 50,000 IU every other week for 40 wk) or a matching placebo for 1 y.

9 l followed by 4000 IU cholecalciferol/d or a matching placebo for 16 wk.

10 ation at 1 of 2 doses (2000 or 4000 IU) or a matching placebo for 16 wk.

11 received 10 to 20 mg/d of escitalopram or a matching placebo for 8 weeks.

12 00 mg, or 150 and 600 mg, respectively, or a matching placebo for a period of 40 weeks, and then to u

13 The active dental gel or a matching placebo gel was applied into the periodontal po

14 ion > or = 12 hours before angiography) or a matching placebo infusion with provisional use of eptifi

15 eeks of treatment with either bupropion or a matching placebo pill (double-blind).

16 istered as 1 nitazoxanide 500-mg tablet or a matching placebo twice daily for 3 days.

17 folic acid, vitamin B6, and vitamin B12 or a matching placebo, and were treated for 7.3 years from Ap

18 month course of 900 mg INH twice weekly or a matching placebo.

19 c acid, vitamin B(6), and vitamin B(12) or a matching placebo.

20 d 2.5 mg of medroxyprogesterone acetate or a matching placebo.

21 rbal extracts (Vineyard [V]), JP alone, or a matching placebo.

22 nhaled salmeterol (100 mug twice daily) or a matching placebo.

23 s (27.3%) receiving a mood stabilizer plus a matching placebo (P=0.40).

24 pressant therapy or a mood stabilizer plus a matching placebo, under conditions generalizable to rout

25 d to continue spironolactone or to receive a matching placebo.

26 400 IU of vitamin D3) and 18,106 received a matching placebo for an average of 7.0 years.

27 enyl treatment (D subjects) or changing to a matching placebo (P subjects) under double-blind conditi

28 (333-mg dose every 8 hours) for 5 days vs a matching placebo regimen.

29 docetaxel (n=402) or the same regimen with a matching placebo replacing pertuzumab (n=406).

30 ects of 40 mEq K/d as KCl supplements with a matching placebo, taken for 3 mo, on measures of potassi

31 5), 40 mg/kg praziquantel and an albendazole-matching placebo (n=626), or an albendazole-matching pla

32 -matching placebo (n=626), or an albendazole-matching placebo and praziquantel-matching placebo (n=62

33 e (10, 30, 60 and 100 ng kg(-1) min(-1)) and matching placebo, in random order, on separate occasions

34 n=79), 350 mg (n=79), and 420 mg (n=80), and matching placebo (n=79) every 4 weeks.

35 2 received oral valacyclovir, acyclovir, and matching placebo in random order for 7-week periods.

36 3) for 28 days, or 40 mg of prednisolone and matching placebo (n=137) for 28 days.

37 (n = 43) versus intravenous crystalloid and matching placebos (n = 55).

38 For the six ICS and matching placebos (beclomethasone-chlorofluorocarbon [CF

39 All regimens included matching placebo such that all volunteers received ident

40 All treatment arms included matching placebos.

41 .5 mg, whereas those on placebo continued on matching placebo.

42 astatin daily following surgery (n = 102) or matching placebo (n = 97).

43 to receive 10 mg/d of ramipril (n = 106) or matching placebo (n = 106) for 24 weeks.

44 eive oral paricalcitol, 2 mug/d (n =115), or matching placebo (n = 112).

45 ginkgo, 40 mg 3 times per day (n = 115), or matching placebo (n = 115).

46 eceive gemfibrozil, 1200 mg/d (n = 1264), or matching placebo (n = 1267).

47 ly [n = 12], 100 mg twice daily [n = 12], or matching placebo [n = 13], starting 26 hours before viru

48 randomised to receive regorafenib (n=133) or matching placebo (n=66).

49 taining either 0.625 mg of CEE (n = 1387) or matching placebo (n = 1421).

50 , both irbesartan and lipoic acid (n=15), or matching placebo (n=14) for 4 weeks.

51 eceived either MC-1, 250 mg/d (n = 1519), or matching placebo (n = 1504) immediately before and for 3

52 to twice daily aciclovir 400 mg (n=1637) or matching placebo (n=1640) for 12-18 months, and were see

53 twice-daily losmapimod (7.5 mg; n = 1738) or matching placebo (n = 1765) on a background of guideline

54 intramuscular injections of 250 mg of 17P or matching placebo, starting at 16 to 20 weeks of gestatio

55 total cumulative dose = 600 mg; n = 181) or matching placebo (n = 88).

56 age (50-200 mg/d) of sertraline (n = 189) or matching placebo tablets (n = 187) for 10 weeks.

57 ining 100 mg of total isoflavones (n=193) or matching placebo (n=193) in 2 divided doses administered

58 0.75 mg/kg per day for 28 days (group 2), or matching placebo for each group.

59 partial NMDA agonist d-cycloserine (n=20) or matching placebo capsules (n=27).

60 atorvastatin the morning after (n = 206) or matching placebo (n = 210), and resumed taking the previ

61 5 mg of spironolactone once daily (n=213) or matching placebo (n=209) with 12 months of follow-up.

62 of medroxyprogesterone acetate (n = 2145) or matching placebo (n = 2236).

63 one titrated from 15 mg to 45 mg (n=2605) or matching placebo (n=2633), to be taken in addition to th

64 ), 8 mg/day (n=284), or 10 mg/day (n=283) or matching placebo (n=278) for 14 weeks.

65 on day 1 and 2 mg orally on days 2 to 3) or matching placebo, granisetron (2 mg orally on days 1 to

66 aricalcitol (1 mug) one time daily (n=30) or matching placebo (n=30) for 52 weeks.

67 hromycin (12 mg/kg/d for 5 days; n = 307) or matching placebo (n = 300), started early during each pr

68 Vitamin D3 (2400 IU/d; n = 315) or matching placebo tablets (n = 308) from pregnancy week 2

69 thromycin, 1200 mg once weekly (n = 321), or matching placebo (n = 322).

70 ed-release 1000 mg twice daily, n = 3279) or matching placebo (n = 3281), and followed up for a media

71 200 mg/d, Week 1; 400 mg/d, Weeks 2 to 4) or matching placebo (n = 80) once daily for 4 wk.

72 one acetate, 5 mg/d for 13 days (n = 45), or matching placebo (n = 22), for 9 months.

73 ned to receive either naltrexone (n = 48) or matching placebo (n = 49) for 12 weeks.

74 mg/d or 120 mg/d of raloxifene (n = 4843) or matching placebo (n = 2447) for 4 years.

75 ne acetate, titrated to 0.1 mg/d (n = 50) or matching placebo (n = 50) for 9 weeks, followed by 2 wee

76 ned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108).

77 mly assigned to receive sertraline (N=68) or matching placebo (N=66); all received intensive individu

78 Eszopiclone, 3 mg (n = 76), or matching placebo (n = 78) for the first 14 nights of CPA

79 ients to receive losartan, 100 mg (n=77), or matching placebo (n=76) within 3 months of transplantati

80 (n=79), 105 mg (n=79), or 140 mg (n=78), or matching placebo (n=78) every 2 weeks; or AMG 145 280 mg

81 followed by 300 mg at weeks 2, 4, and 8), or matching placebo.

82 at baseline and 225 mg at weeks 4 and 8), or matching placebo.

83 dministered ramipril 10 mg per day (n=82) or matching placebo (n=83) for 24 weeks in a randomized, do

84 of 10 to 20 mg/d of escitalopram (n = 85) or matching placebo (n = 92).

85 5 mg medroxyprogesterone acetate (n=8506) or matching placebo (n=8102).

86 e of 1 mg, 2.5 mg, 5 mg, or 10 mg TA-8995 or matching placebo; 10 mg TA-8995 plus 20 mg atorvastatin;

87 avenous then 200 mg oral daily; n=22,929) or matching placebo (n=22,923).

88 receive either rimonabant 20 mg (n=9381) or matching placebo (n=9314).

89 ocated clopidogrel 75 mg daily (n=22,961) or matching placebo (n=22,891) in addition to aspirin 162 m

90 subjects received 4 rounds of albendazole or matching placebo with 3-month intervals, for 3 consecuti

91 150 international units of human IFN alfa or matching placebo 3 times per day for 24 weeks by the oro

92 location to receive 1 mg oral anastrozole or matching placebo every day for 5 years.

93 atients received 80 mg atorvastatin (ATV) or matching placebo for a 12-week treatment period with a m

94 omized, controlled trial, cytochalasin B (or matching placebo) was administered to the site of a succ

95 o receive two injections of betamethasone or matching placebo 24 hours apart.

96 oral dose of the ACE inhibitor captopril or matching placebo.

97 le-dose treatment with sildenafil citrate or matching placebo.

98 ere randomly assigned to receive cytisine or matching placebo for 25 days; participants in both group

99 ive treatment with atorvastatin (80 mg/d) or matching placebo between 24 and 96 hours after hospital

100 ted dosage of acetazolamide (up to 4 g/d) or matching placebo for 6 months.

101 e fish oil capsules (four 1-g capsules/d) or matching placebo on day 7 after graft creation.

102 zed to receive either tolvaptan (30 mg/d) or matching placebo, within 48 hours of admission.

103 d weight-based ribavirin (1000-1200 mg/d) or matching placebo.

104 mg/d, and medroxyprogesterone, 2.5 mg/d, or matching placebo.

105 receive pentoxifylline 400 mg p.o. t.i.d. or matching placebo for 1 year after cardiac transplantatio

106 misation to rifampicin 300 mg twice daily or matching placebo (50 mg riboflavin capsules), stratified

107 rtan at a target dose of 32 mg once daily or matching placebo and followed up for a median of 38 mont

108 ere randomized to 40 mg simvastatin daily or matching placebo for 5 years, which, on average, reduced

109 :1) to receive oral tamoxifen 20 mg daily or matching placebo for 5 years.

110 ly assigned sildenafil 40 mg thrice daily or matching placebo for 9 weeks.

111 either 500 mg of levofloxacin once daily or matching placebo for seven days during the expected neut

112 omly assigned to atorvastatin 10 mg daily or matching placebo in a randomised double-blind placebo-co

113 ther nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacc

114 international units capsules twice-daily or matching placebo tablets and capsules.

115 oral vandetanib 300 mg per day once daily or matching placebo.

116 atin (20 mg) plus ezetimibe (10 mg) daily or matching placebo.

117 an (n=3803, titrated to 32 mg once daily) or matching placebo (n=3796), and followed up for at least

118 sease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 mo

119 nuous oral sorafenib (400 mg twice-daily) or matching placebo combined with TACE using drug-eluting b

120 ), to oral RO5093151 (200 mg twice daily) or matching placebo for 12 weeks.

121 ns of atopaxar (50, 100, or 200 mg daily) or matching placebo for 24 weeks and followed up for an add

122 d to add raltegravir (400 mg twice daily) or matching placebo for 24 weeks.

123 bosis to receive vorapaxar (2.5 mg daily) or matching placebo in a 1:1 ratio.

124 ding dose followed by 7.5 mg twice daily) or matching placebo in a 3:3:2 ratio.

125 to either metformin (850 mg twice daily) or matching placebo in block sizes of four.

126 00 mg in two 150 mg tablets, twice daily) or matching placebo tablets using an interactive voice and

127 mized to receive rimonabant (20 mg daily) or matching placebo, and underwent coronary intravascular u

128 ose followed by 50, 100, or 200 mg daily) or matching placebo.

129 andesartan (target dose 32 mg once daily) or matching placebo.

130 or 200 mg twice daily, 200 mg once daily, or matching placebo [n = 16], in each group starting 28 hou

131 5, or 10 mg oral preladenant twice daily, or matching placebo for 12 weeks.

132 ndomized to receive pravastatin 40 mg/day or matching placebo for a median follow-up period of 5 year

133 usted to a maximum dose of 600 mg per day or matching placebo for up to 8 weeks.

134 d either 150 mg of anacetrapib once a day or matching placebo with a meal for 10 days in each crossov

135 ceive 1 year of oral neratinib 240 mg/day or matching placebo.

136 assigned to candesartan 16 mg once a day or matching placebo.

137 to receive oral neratinib 240 mg per day or matching placebo.

138 6 months of oral spironolactone 25 mg/day or matching placebo.

139 arginine (goal dose of 3 g 3 times a day) or matching placebo for 6 months.

140 2 mg per kilogram of body weight per day) or matching placebo for one year and were followed for an a

141 eive idebenone (300 mg three times a day) or matching placebo orally for 52 weeks.

142 d to daily sorafenib (400 mg twice a day) or matching placebo plus gemcitabine (1,250 mg/m(2) per day

143 receive oral buparlisib (100 mg per day) or matching placebo starting on day 1 of cycle 1, plus intr

144 1 to receive oral buparlisib (100 mg/day) or matching placebo, starting on day 15 of cycle 1, plus in

145 zine (12 mg/day, 24 mg/day, or 36 mg/day) or matching placebo.

146 ACAT inhibitor pactimibe (100 mg per day) or matching placebo.

147 ally three times daily (40 mg/kg per day) or matching placebo.

148 (at a dose of 60, 120, or 240 mg per day, or matching placebo) for 12 weeks after engraftment.

149 vely, and 25 mg daily for another 8 days, or matching placebo at the same times.

150 domly assigned to receive 50 mg/d of DHEA or matching placebo for 6 months.

151 tered oral NAC (3000 mg in divided doses) or matching placebo 165 min before the infusion of saline a

152 owed by 200 mg every 12 h for five doses, or matching placebo, within 6 h of stroke onset.

153 al administration of 20 mg of doxycycline or matching placebo pill twice a day at least 2 days prior

154 0 mg of vitamin C and 400 IU of vitamin E or matching placebo between the 9th and 16th weeks of pregn

155 three), to receive once-daily eltrombopag or matching placebo dose adjusted from 50 mg to a maximum d

156 receive 150 mg of testosterone enanthate or matching placebo intramuscularly every 2 weeks for 6 mon

157 10 mg/kg midday, and 20 mg/kg in evening) or matching placebo for 48 weeks.

158 Fasudil or matching placebo was force-titrated from 20 mg three tim

159 Patients received either fludrocortisone or matching placebo at highest tolerated doses from 0.05 mg

160 g/kg intravenous ramucirumab plus FOLFIRI or matching placebo plus FOLFIRI every 2 weeks until diseas

161 oxil fumarate and emtricitabine (TDF-FTC) or matching placebo once daily.

162 nation tenofovir-emtricitabine (TDF-FTC), or matching placebo--and followed monthly for up to 36 mont

163 maximum dosage of 3600 mg/d of gabapentin or matching placebo.

164 or secondary RP received 0.9% MQX-503 gel or matching placebo during the treatment period.

165 ssigned to receive either subcutaneous GH or matching placebo titrated to the upper quartile of norma

166 ver 10 min then infusion of 1 g over 8 h) or matching placebo.

167 d by a constant infusion of 2 g per hour, or matching placebo.

168 or women who had not had a hysterectomy), or matching placebo, and 400 IU of vitamin E twice daily pl

169 lus paclitaxel (80 mg/m(2) intravenously) or matching placebo plus paclitaxel.

170 s of radium-223 (50 kBq/kg intravenously) or matching placebo, with one injection given every 4 weeks

171 er kilogram of body weight intravenously) or matching placebo; one injection was administered every 4

172 ral doses of cholecalciferol (300,000 IU) or matching placebo at baseline and 8 weeks.

173 , 70, 210, or 420 mg SC; 21 or 420 mg IV; or matching placebo.

174 s either intravenous ramucirumab 10 mg/kg or matching placebo on day 1 of repeating 21-day cycles, un

175 nous injections of radium-223 (50 kBq/kg) or matching placebo; one injection was given every 4 weeks.

176 Leflunomide or matching placebo added to existing methotrexate therapy.

177 protein kinase Cbeta inhibitor, LY333531, or matching placebo once a day for 7 days before vascular f

178 Metformin or matching placebo titrated up to 500 mg twice daily for c

179 AH were to be randomized to aspirin 81 mg or matching placebo and simvastatin 40 mg or matching place

180 aily oral treatment with linagliptin 5 mg or matching placebo for 24 weeks.

181 tronidazole 750 mg plus miconazole 200 mg or matching placebo for 5 consecutive nights each month for

182 h PAH were randomized to anastrozole 1 mg or matching placebo in a 2:1 ratio.

183 to receive either oral naldemedine 0.2 mg or matching placebo once a day for 12 weeks.

184 ended-release exenatide at a dose of 2 mg or matching placebo once weekly.

185 mised to receive oral ganciclovir 1000 mg or matching placebo three times a day.

186 eceive tozadenant 60, 120, 180, or 240 mg or matching placebo twice daily for 12 weeks.

187 Thiamine 200 mg or matching placebo twice daily for 7 days or until hospita

188 Patients received oral vorinostat 300 mg (or matching placebo) twice daily on days 1, 2, 3, 8, 9, 10,

189 The study drugs (acetylcysteine 1200 mg or matching placebo) were administered orally twice daily f

190 or matching placebo and simvastatin 40 mg or matching placebo.

191 oral dose of sildenafil 12.5, 25 or 50 mg or matching placebo.

192 ither twice-daily oral ranolazine 1000 mg or matching placebo.

193 omly assigned (1:1) to gefitinib (500 mg) or matching placebo by simple randomisation with no stratif

194 e randomized to receive ezetimibe (10 mg) or matching placebo for 6 months in addition to usual treat

195 ts per day of sodium clodronate (2080 mg) or matching placebo for up to 3 years (metastatic disease)

196 se of SCH 530348 (10 mg, 20 mg, or 40 mg) or matching placebo in a 3:1 ratio in a multicentre interna

197 ed 1:1 to receive escitalopram (10-20 mg) or matching placebo in addition to optimal heart failure th

198 ive either NDI-010976 (20, 50, or 200 mg) or matching placebo in period 1, followed by the alternate

199 1:1:1 ratio to ozanimod (0.5 mg or 1 mg) or matching placebo once daily for 24 weeks by an independe

200 either a low dose of varenicline (0.5 mg) or matching placebo pill (double-blind, random order) befor

201 e) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation f

202 tep 1 drug is chlorthalidone (12.5-25 mg) or matching placebo, and the step 2 drug is atenolol (25-50

203 aily erythromycin ethylsuccinate (400 mg) or matching placebo.

204 ther intravenous montelukast (7 or 14 mg) or matching placebo.

205 nd the step 2 drug is atenolol (25-50 mg) or matching placebo.

206 1000 mg), high-dose guggulipid (2000 mg), or matching placebo.

207 N=67), at a maximal daily dose of 200 mg, or matching placebo (N=71).

208 Doxycycline, 200 mg, or matching placebo daily for 12 months.

209 ions of AMG 145 70 mg, 105 mg, or 140 mg, or matching placebo every 2 weeks; or subcutaneous injectio

210 ons of AMG 145 280 mg, 350 mg, or 420 mg, or matching placebo every 4 weeks.

211 Hydroxychloroquine, 400 mg, or matching placebo once daily for 48 weeks.

212 ing ephedra [12 mg] and caffeine [40 mg]) or matching placebo were administered in a crossover fashio

213 ng per kilogram of body weight per minute or matching placebo for 48 hours, in addition to accepted t

214 ly assigned to either NV1FGF at 0.2 mg/mL or matching placebo (visually identical) in a 1:1 ratio.

215 r 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections.

216 of 50 mug, 150 mug, 300 mug, or 600 mug, or matching placebo (n=55 in each group), or to open-label

217 fixed-dose tablets (also known as NB16), or matching placebo twice a day, given orally for 56 weeks.

218 fter treatment with either sodium nitrite or matching placebo.

219 eceived either 10 mg of olanzapine orally or matching placebo daily on days 1 through 4.

220 receive 4.5 gm or 6 gm of sodium oxybate or matching placebo once per night for 8 weeks.

221 g testosterone daily by transdermal patch or matching placebo for 12 weeks, in addition to their curr

222 anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients).

223 ase inhibitor voxilaprevir (150 patients) or matching placebo (150 patients) once daily for 12 weeks.

224 320 mg of sotalol per day (151 patients) or matching placebo (151 patients), and followed for 12 mon

225 rget dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).

226 l sofosbuvir and ribavirin (207 patients) or matching placebo (71) for 12 weeks.

227 Pioglitazone or matching placebo.

228 the biomarker-directed arm, prednisolone or matching placebo was given according to the blood eosino

229 ocated by computer to either the quadpill or matching placebo for 4 weeks; this treatment was followe

230 specific volume of study drug (reslizumab or matching placebo) on the basis of the patient's body wei

231 mg/d based on tolerability and response) or matching placebo (n = 99).

232 ceive 420-mg silymarin, 700-mg silymarin, or matching placebo administered 3 times per day for 24 wee

233 ipants in a 1:1 ratio to either sorafenib or matching placebo.

234 Oral doses of 0.5 or 2.0 g SRT2104 or matching placebo were administered once daily for 28 day

235 h 4:1 allocation to oral AA (87 subjects) or matching placebo (23 subjects).

236 once-daily, fixed-dose combination tablet or matching placebo for 12 weeks.

237 received oral cabotegravir 30 mg tablets or matching placebo once daily during a 4 week oral lead-in

238 receive 50, 100, or 150 mg of thalidomide or matching placebo.

239 ased to 200 mg twice daily, if tolerated) or matching placebo twice daily.

240 ere randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 we

241 a 1:1 ratio to 40 mg of adalimumab weekly or matching placebo for 12 weeks.

242 o 25 mg rifalazil once weekly for 8 weeks or matching placebo.

243 f dalteparin per kilogram of body weight) or matching placebo administered subcutaneously twice daily

244 se of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization.

245 g or 5.25 mg per kilogram of body weight) or matching placebo, given in two or four short courses for

246 weeks (Q2W) x3, 420 mg every 4 weeks x2, or matching placebo.

247 0 mg per day for age 6 months to 5 years) or matching placebo.

248 ombination of the 2 medications (n = 20), or matching placebos (n = 24).

249 mined according to body weight) (group A) or matching placebos (group B).

250 d) plus alpha-lipoic acid (ALA; 600 mg/d) or matching placebos for 6 months (NCT00237718); 238 patien

251 y) with ribavirin (1000 or 1200 mg daily) or matching placebos during the 12-week double-blind period

252 OBI/FTC/TDF or EFV/FTC/TDF, once daily, plus matching placebo.

253 ive EVG/COBI/FTC/TDF or ATV/RTV+FTC/TDF plus matching placebos, administered once daily.

254 =628), 440 mg albendazole and a praziquantel-matching placebo (n=625), 40 mg/kg praziquantel and an a

255 lbendazole-matching placebo and praziquantel-matching placebo (n=628).

256 il hospital discharge (n = 84) or to receive matching placebo (n = 76).

257 administered according to body weight or to matching placebo for ribavirin.

258 eeks (q4-wk), every 12 weeks (q12-wk), or to matching placebo to week 52.

259 iacin with 40 mg of laropiprant daily versus matching placebo, in addition to effective statin-based

260 atin 20 mg plus ezetimibe 10 mg daily versus matching placebo.

261 trial of sertraline 50 to 200 mg/day versus matching placebo for 12 weeks.

262 lgia within 3 weeks of open-label use versus matching placebo.

263 n E (alpha-tocopherol) 1,000 U daily, versus matching placebos in 1,005 asymptomatic, apparently heal

264 ablet containing either 0.625 mg/d of CEE vs matching placebo; in the estrogen plus progestin trial,

265 of treatment with d-vitamin E (1600 IU/d) vs matching placebo.

266 lus and 1-mg/kg per hour 5-hour infusion, vs matching placebo.

267 Latrepirdine (20 mg) vs matching placebo administered orally 3 times daily for 2

268 og/kg/min titrated to 0.10 microg/kg/min) vs matching placebo, starting 1 hour prior to angiography a

269 ning CEE (0.625 mg/d) plus MPA (2.5 mg/d) vs matching placebos.

270 fa, 40,000 U subcutaneously, once weekly vs. matching placebo.

271 igate oral iron polysaccharide compared with matching placebo with the primary end point of change in

272 ve either oral tamoxifen 20 mg per day (with matching placebo in place of anastrozole) or oral anastr

273 zole) or oral anastrozole 1 mg per day (with matching placebo in place of tamoxifen) for 5 years.

274 b (45 mg/day) or erlotinib (150 mg/day) with matching placebo.

275 75 mg bictegravir or 50 mg dolutegravir with matching placebo plus the fixed-dose combination of 200

276 ofovir disoproxil fumarate 300 mg, each with matching placebo.

277 or 300 mg tenofovir disoproxil fumarate with matching placebo.

278 e (E/C/F/tenofovir disoproxil fumarate) with matching placebo.

279 tenofovir disoproxil fumarate (300 mg), with matching placebo, once daily for 96 weeks.

280 tenofovir disoproxil fumarate (300 mg), with matching placebo.

281 200 mg and tenofovir alafenamide 25 mg, with matching placebo, once a day for 144 weeks.

282 abacavir 600 mg, and lamivudine 300 mg, with matching placebo, once daily for 144 weeks.

283 ibavirin versus oseltamivir monotherapy with matching placebo for the treatment of influenza in 50 si

284 0 IU of oxytocin intramuscularly, along with matching placebos for the treatment they did not receive

285 or based regimen); regimens were masked with matching placebos.

286 pitavastatin 4 mg or pravastatin 40 mg with matching placebos once daily orally for 12 weeks, follow